


LITHIUM - Patients newly prescribed Lithium



Patient should continue on agreed prescription and receive their regular monitoring At each review appointment reinforce the need for follow-up blood tests and to not make lifestyle or medication changes while on lithium.

Ensure they have their "purple book"

Refer if any concerns as per the Norfolk and Waveney Shared Care Protocol.

Therapeutics Advisory Group



Title	LITHIUM - Patients newly prescribed Lithium		
Description of policy	To inform healthcare professionals		
Scope	Norfolk and Waveney Integrated Care System		
Prepared by	Norfolk and Waveney ICB Medicines Optimisation Team		
Impact Assessment	Please indicate impact assessment outcome:		
(Equalities and	Positive impact		
Environmental)	Adverse impact - low - action plan completed as per guidance Adverse impact - medium - action plan completed as per guidance Adverse impact - high - action plan completed as per guidance		
	No impact		
	No policy will be approved without a completed equality impact		
	assessment		
Other relevant approved documents	Lithium shared care agreement		
Evidence base /	Level of Evidence:		
Legislation	A. based on national research-based evidence and is considered		
g	best evidence		
	B. mix of national and local consensus		
	C. based on local good practice and consensus in the absence of		
	national research based information.		
Dissemination	Is there any reason why any part of this document should not be		
	available on the public web site? ☐ Yes / No ☒		
Approved by	Norfolk & Waveney Therapeutics Advisory Group (TAG) July 2025		
Authorised by	Medicines Optimisation Programme Board on behalf of the ICS (July 2025)		
Review date and by whom	Medicines Optimisation Team – July 2027		
Date of issue	July 2025		

Version Number	Author	Purpose / Change	Date
1.0	MO Team	To support prescribing	July 2025